Forskning ved Københavns Universitet - Københavns Universitet

Forside

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • P Iversen
  • C J Tyrrell
  • A V Kaisary
  • J B Anderson
  • L Baert
  • T Tammela
  • M Chamberlain
  • K Carroll
  • K Gotting-Smith
  • G R Blackledge
To compare the efficacy, tolerability, and quality of life benefits of bicalutamide (Casodex) 150-mg/day monotherapy and castration in previously untreated nonmetastatic (M0) advanced prostate cancer.
OriginalsprogEngelsk
TidsskriftUrology
Vol/bind51
Udgave nummer3
Sider (fra-til)389-96
Antal sider8
ISSN0090-4295
StatusUdgivet - 1998

ID: 48470739